<p class="bodytext">Marksans Pharma on Monday said it is recalling 11,279 bottles of diabetes drug Metformin extended-release tablets due to presence of a cancer-causing contaminant.</p>.<p class="bodytext">The company has issued a voluntary recall of one batch of Metformin extended-release tablets (USP 500 mg) due to the detection of NDMA (N-nitrosodimethylamine), Marksans Pharma said in a regulatory filing.</p>.<p class="bodytext">The recalled batch contains 11,279 bottles, it added. Metformin extended-release tablets are indicated as an adjunct to diet and exercise to improve blood glucose control in adults with type 2 diabetes mellitus.</p>
<p class="bodytext">Marksans Pharma on Monday said it is recalling 11,279 bottles of diabetes drug Metformin extended-release tablets due to presence of a cancer-causing contaminant.</p>.<p class="bodytext">The company has issued a voluntary recall of one batch of Metformin extended-release tablets (USP 500 mg) due to the detection of NDMA (N-nitrosodimethylamine), Marksans Pharma said in a regulatory filing.</p>.<p class="bodytext">The recalled batch contains 11,279 bottles, it added. Metformin extended-release tablets are indicated as an adjunct to diet and exercise to improve blood glucose control in adults with type 2 diabetes mellitus.</p>